Alvotech - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALVO Nasdaq 2836 www.alvotech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alvotech

Alvotech (ALVO) Secures $100 Million in New Financing - Jan 9th, 2026 1:16 am
Alvotech announces planned CEO succession and leadership transition - Jan 6th, 2026 5:15 am
Alvotech (NasdaqGM:ALVO) Valuation Check After New $100 Million GoldenTree Term Loan for Biosimilar Growth - Jan 4th, 2026 8:09 pm
Alvotech Secures Term Loan Facility of USD 100 Million - Dec 31st, 2025 2:30 pm
Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma - Dec 22nd, 2025 12:00 am
Alvotech (ALVO): Firm Reaffirms 2025 Growth Outlook - Dec 21st, 2025 7:03 am
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® - Dec 19th, 2025 1:40 am
Is Alvotech (NasdaqGM:ALVO) Undervalued After Its Recent 36% Three-Month Share Price Slide? - Dec 18th, 2025 7:10 pm
Is There a Long Term Opportunity in Alvotech After a 58% Share Price Slide? - Dec 18th, 2025 12:14 pm
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday as Investors Digest Latest Economic Data - Dec 17th, 2025 7:05 am
Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering - Dec 17th, 2025 12:30 am
Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Global Product Launches and Enhance Liquidity Position, reaffirms 2025 outlook and provides 2026 guidance - Dec 16th, 2025 9:48 am
Alvotech (ALVO): A Bull Case Theory - Dec 4th, 2025 11:39 am
Alvotech (ALVO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Regulatory Challenges - Nov 24th, 2025 6:01 pm
Alvotech's (NASDAQ:ALVO) Performance Raises Some Questions - Nov 24th, 2025 12:50 pm
Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area - Nov 24th, 2025 3:30 am
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab) - Nov 20th, 2025 2:00 am
Alvotech (NASDAQ:ALVO) Just Reported And Analysts Have Been Lifting Their Price Targets - Nov 16th, 2025 5:23 am
Alvotech (ALVO) Reports Q3 Loss, Misses Revenue Estimates - Nov 12th, 2025 3:55 pm
Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update - Nov 12th, 2025 2:40 pm